433 related articles for article (PubMed ID: 18331118)
1. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
2. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of health care costs and utilization patterns for patients with gout.
Park H; Rascati KL; Prasla K; McBayne T
Clin Ther; 2012 Mar; 34(3):640-52. PubMed ID: 22381710
[TBL] [Abstract][Full Text] [Related]
4. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
5. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
Wu EQ; Patel PA; Mody RR; Yu AP; Cahill KE; Tang J; Krishnan E
J Rheumatol; 2009 May; 36(5):1032-40. PubMed ID: 19369467
[TBL] [Abstract][Full Text] [Related]
6. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
7. Benefit restrictions and gout treatment.
Wang SM; Aranda GA; Gao S; Patel BV
J Manag Care Pharm; 2013; 19(9):773-82. PubMed ID: 24156646
[TBL] [Abstract][Full Text] [Related]
8. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
9. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus.
Delea TE; Gokhale M; Makin C; Hussein MA; Vanderpoel J; Sandman T; Chang J; Sung J; Pinkston P; Gause D; Jackson M
J Manag Care Pharm; 2007 May; 13(4):349-59. PubMed ID: 17506601
[TBL] [Abstract][Full Text] [Related]
10. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
13. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
14. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
[TBL] [Abstract][Full Text] [Related]
15. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
16. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
17. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
19. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
20. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
